XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.23.3

Segment Reporting | 12 Months Ended
--- | ---
Jun. 30, 2023
Statement [LineItems] |
Segment Reporting | NOTE 4. SEGMENT REPORTING Identification of reportable operating segments Operating segments are reported in a manner consistent with internal reports which are reviewed and used by Management and the Board of Directors (who are identified as the Chief Operating Decision Makers (‘CODM’)). The Group operates in one operating segment, being Cancer Immunotherapy.
Operating segment information June 30, 2023 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 191,721 |  |  |  | — |  |  |  | 191,721 |
Grant income |  |  | 3,314,001 |  |  |  | — |  |  |  | 3,314,001 |
Net gain on fair value movement of warrants |  |  |  |  |  |  | 131,896 |  |  |  | 131,896 |
Net gain on foreign exchange |  |  |  |  |  |  | 623,511 |  |  |  | 623,511 |
Interest income |  |  |  |  |  |  | 938,999 |  |  |  | 938,999 |
Total revenue and other income |  |  | 3,505,722 |  |  |  | 1,694,406 |  |  |  | 5,200,128 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (41,431,305 | ) |  |  | 1,534,957 |  |  |  | (39,896,348 | )
Profit/(loss) before income tax expense |  |  | (41,431,305 | ) |  |  | 1,534,957 |  |  |  | (39,896,348 | )
Income tax expense |  |  | — |  |  |  | — |  |  |  | — |
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (39,896,348 | )
Total segment assets |  |  | 147,448,990 |  |  |  | — |  |  |  | 147,448,990 |
Total segment liabilities |  |  | 10,979,601 |  |  |  | — |  |  |  | 10,979,601 |
Operating segment information June 30, 202 2 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | 170,369 |  |  |  | — |  |  |  | 170,369 |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 84,018 |  |  |  | — |  |  |  | 84,018 |
Grant income |  |  | 4,459,974 |  |  |  | — |  |  |  | 4,459,974 |
Net gain on fair value movement of warrants |  |  | — |  |  |  | 591,070 |  |  |  | 591,070 |
Net gain on foreign exchange |  |  | — |  |  |  | 1,228,122 |  |  |  | 1,228,122 |
Interest income |  |  | — |  |  |  | 224,520 |  |  |  | 224,520 |
Total revenue and other income |  |  | 4,714,361 |  |  |  | 2,043,712 |  |  |  | 6,758,073 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (33,929,768 | ) |  |  | 1,718,976 |  |  |  | (32,210,792 | )
Profit/(loss) before income tax expense |  |  | (33,929,768 | ) |  |  | 1,718,976 |  |  |  | (32,210,792 | )
Income tax expense |  |  |  |  |  |  |  |  |  |  | (34 | )
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (32,210,826 | )
Total segment assets |  |  | 102,169,550 |  |  |  | — |  |  |  | 102,169,550 |
Total segment liabilities |  |  | 8,092,184 |  |  |  | — |  |  |  | 8,092,184 |
Operating segment information June 30, 2021 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 312,841 |  |  |  | — |  |  |  | 312,841 |
Grant income |  |  | 3,549,965 |  |  |  | — |  |  |  | 3,549,965 |
Net gain on fair value movement of warrants |  |  | — |  |  |  | — |  |  |  | — |
Net gain on foreign exchange |  |  | — |  |  |  | — |  |  |  | — |
Interest income |  |  | — |  |  |  | 105,327 |  |  |  | 105,327 |
Total revenue and other income |  |  | 3,862,806 |  |  |  | 105,327 |  |  |  | 3,968,133 |
Segment Result |  |  | (19,665,904 | ) |  |  | (10,236,687 | ) |  |  | (29,902,591 | )
Profit/(loss) before income tax expense |  |  | (19,665,904 | ) |  |  | (10,236,687 | ) |  |  | (29,902,591 | )
Income tax expense |  |  |  |  |  |  |  |  |  |  | (33 | )
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (29,902,624 | )
Total segment assets |  |  | 82,030,533 |  |  |  | — |  |  |  | 82,030,533 |
Total segment liabilities |  |  | 8,758,922 |  |  |  | — |  |  |  | 8,758,922 |

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | immp_StatementLineItems
Namespace Prefix: | immp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration